Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ:HZNP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
From Alpine Immune Sciences, Inc. and Horizon Therapeutics plc
Via Business Wire
This Biotech CEO Is Trying To Cure His Son's Rare Disease
Few questions stump Tim Walbert. But the Horizon Therapeutics CEO is still working to answer one of them from his son. 
Via Investor's Business Daily
Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater
From Horizon Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
From Horizon Therapeutics plc
Via Business Wire
7 Drug Stocks to Buy Now While They’re Still on Sale
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. 
Via InvestorPlace
Topics Supply Chain
New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
From Horizon Therapeutics plc
Via Business Wire
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Stock Market Rally Keeps Running On Tesla, Nvidia, Fed Decision, Jobs Report: Weekly Review
But the Nasdaq is starting to look extended. 
Via Investor's Business Daily
Topics Bonds Economy Stocks
Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
From Horizon Therapeutics plc
Via Business Wire
Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro, during Q3, Horizon Therapeutics (NASDAQ:HZNP) earned $331.54 million, a 142.86% increase from the preceding quarter. Horizon Therapeutics also posted a... 
Via Benzinga
Horizon Pharma plc (HZNP) Q3 2021 Earnings Call Transcript
HZNP earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
CFO Retirement Plan Undoes Horizon Therapeutics Stock After Beat-And-Raise
Chief Financial Officer Paul Hoelscher will retire on May 16. 
Via Investor's Business Daily
Topics Retirement
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
From Horizon Therapeutics plc
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
From Horizon Therapeutics plc
Via Business Wire
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Beam Therapeutics Stock Flashes Renewed Technical Strength
On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before. 
Via Investor's Business Daily
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS